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The coronary lesion in unstable angina consists of dis-
rupted atherosclerotic plaque with nonocclusive intra-
luminal thrombus, which frequently persists despite
heparin anticoagulation, A 12 hour infusion of recom-
binant tissue-type plasminogen activator combined with
heparin effectively lyses the thrombus and stabilizes the
The current medical treatment for unstable angina pectori s
con sists of combination therapy with nitrate s, beta-receptor
anti-pl atelet blockers , calcium channel antagoni sts and anti-
platelet aggregation drugs (1-7) . The rationale for this ap-
proach is based on the recognition of the role of coronar y
vasos pasm (8), atherosclerosis (9) and platelet aggregation
( 10) in the pathogenesis of the disease . In addition to these
mechanism s, intracoronary thrombosis may play an impor-
tant role ; consequently , thrombolytic therapy with clot-spe-
cific agents, such as tissue-type plasminogen activator, might
be indicated for unstable angin a . In this article we review
two important aspects that have formed the basis of our
approach to the treatment of unstable angina with recom -
binant tissue-type plasminogen activator (rt-PA). These in-
clude the characteristics of the coronary artery lesion s in
unstable angina and the role of thrombus formation in the
pathogenesis of the syndrome. In addition, we summarize
our results, which indicate that thrombol ytic therapy can
reverse the arterial proce ss responsible for recurrent isch-
emi a at rest, and stabilize the clinic al condition, until more
definiti ve interventional measures may be implicated.
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clinical syndrome but is associated with a high incidence
of bleeding. Therapeutic schemes of thrombolytic ther-
apy associated with a lower bleeding frequency may be
useful for the treatment of unstable angina,
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Characteristics of the Coronary Artery
Lesions in Unstable Angina
Pathologic findings . Levin and Fallon ( I I) character-
ized the atherosclerotic lesions in patients with unstable
angina or acute myocardial infarction by correlating the
postmortem angiographic morphology with histologic sec-
tions of the stenotic coronary arter ies. When the coro nary
angiogram revealed a narro wed segment with irregular bor-
ders or intraluminal filling defects , the lesion was usually
found to consist of a ruptured atherosclerotic plaque in as-
sociation with a subocclusive thrombus . Fallon and Wather
(personal communication) examined the coronary arterie s
from 3 1 patients with unstable angina postmortem and found
that 90% had at least one focus of plaque hemorrhage. Fifly-
nine percent of these plaque hemorrhages were associated
with plaque rupture and intraluminal thrombus and a further
28% of patient s had mural thrombu s.
Falk (12) presented evidence that the period of unstable
angina preced ing term inal myocard ial infarction was char-
acte rized by repet itive episodes of thrombus formation and
fragmen tation . Thirteen of 15 patient s studied showed lay-
ered thrombu s with thrombotic material of diffe rent ages .
Thi s was assoc iated with peripheral micro embolization and
microinfarcts in approximately half of the patients. Davies
and Thomas ( 13) also confirmed that the majority of patien ts
who die suddenly show plaque fissures. nonocclu sive intra-
coronary thrombus and a high incidence of platelet-
aggrega te emboli.
Angiographic findings. Vetrovec et al. (14) found thrombi
in 6. 2% of coronary angiograms from patients with unstable
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angina. whereas Holmes et al. (15) found thrombi in only
1.3% of 1,202 patients. In both of these studies the interval
from onset of symptoms 10 angiography was long (I to 3
months), and the criteria for entry into the study were not
rigorously defined.
In most recent studies coronary angiography has been
performed in closer associationwith the onset of symptoms.
In these studies a much higher incidence of thrombus was
observed (16). The highest reported incidence rate of coro-
nary thrombus (85%) occurred in a study by Vetrovec et
al. (17), in which angiography was performed within 5 days
of the onset of symptoms and in which strict electrocardio-
graphic (ECG) criteria were used. Capone et al. (18) also
reportedthat the incidenceof coronary thrombus washighest
in patients undergoing angiography within24 hours of chest
pain, whereas it decreased to 28% in patients whose most
recent chest pain episode had occurred [ to 14 days pre-
viously. The difference in the incidence of thrombi may
reflect ongoing endogenous thrombolysis, which may re-
duce the size of the thrombus over time until it becomes
invisible with current angiographic techniques.
Angioscopic findings. Sherman et al. (1 9), using intra-
operative angioscopy in 10 patients with unstable angina,
provided direct in vivo evidence that rest angina is related
to subocclusivc thrombus in association with irregular, ul-
cerated hemorrhagic endothelium. They also showed that
coronary angiography was less sensitive than angioscopy
with only one of the seven thrombi and only one of four
complex plaques being detected angiographically in the group
with unstable angina. In 17 patients with stable angina,
complex lesions and thrombi were not seen during intra-
operative angioscopy, and angiography correctly identified
their absence.
ATHEROSCLEROTIC PLAQUE
Similarities Between Coronary Artery
Lesions in Unstable Angina and in Acute
Myocardial Infarction After Reperfusion
Angiographic lesions in unstable angina. Ambrose et
al. (20,2 1)classifiedcoronary artery lesions with respect to
their morphologyas eitherconcentric or eccentric. Eccentric
lesions were subdivided into type I with smooth borders and
type II with irregular borders. In addition, few patients
presented with multiple irregularities. Patients with unstabIe
angina had a high frequency of type II eccentric lesions,
whereas patients with stable symptoms rarely showed le-
sions with irregular borders. Ambrose et al. postulated that
the type II eccentric lesion represented a ruptured athero-
sclerotic plaque with subocclusive thrombus.
Angiographic lesions in acute myocardial infarction
after reperfusion. Ambrose et al. (22) found that eccentric
type II lesions commonly occur in patients with acute or
recent myocardial infarction and also in patients who have
undergone successful thrombolysis with intracoronary strep-
tokinase. A more recent review (23) of the coronary angio-
graphic morphology in 33 patients with acute myocardial
infarction after successful reperfusion with rt-PA revealed
type II eccentric lesions in 28 of the patients. This angio-
graphic morphology was indistinguishable from chat seen
in unstable angina.
A Unifying Concept for the Pathogenesis of
the Ischemic Syndrome in Unstable Angina
and Acute Myocardial Infarction
The diagram in Figure I, modified from Davies and
Thomas (13), explains how the acute ischemic syndromes
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Figure J. Diagram of the arterial lesions underlying
the ischemic events occurring in acute myocardial in-
farction and in both stable and unstable angina. For
explanation. sec text. (Modified from Daviesand Thomas
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occurring in hath unstable angina and acute myocardial in-
farction are caused by different phases of the same under-
lying arterial pathologic process. A stable atherosclerotic
plaque develops ncovascularization at its base. These ves-
sels are fragile and may rupture with bleeding into the plaque.
Because of increased pressure in the plaque. the fibrous cap
thins and ultimately ruptures, leading to a variable extent
of thrombus formation , depending on the severity of the
fi xed underlying atherosclerotic lesion. This process may
stabilize becauseof endogenous thrombolysis with or with-
out subsequent expansion of the plaque leading to stable
angina. It may also progress to complete occlusion and
myocardial infarction. Although occlusive thrombosis can
efficiently be reversed by thrombolytic therapy. it is un-
certain whether thrombolysis is beneficial to patients with
unstable angina presenting with subocclusive thrombus and
intraplaque hemorrhage.
Alternative Approaches to the
Treatment of Thrombosis Associated With
Unstable Angina
Lawrence et al. (24) studied 40 patients with unstable
angina who were randomized either to intravenous strep-
tokinase therapy followed by coumadinor to coumadin ther-
apy alone. A significant reduction in the 6 month incidence
of sudden death and myocardial infarction was observed in
the group receiving thrombolytic therapy. Anticoagulation
therapy alone has also been shown to favorably affect the
outcome in patients with unstable angina. Telford and Wil-
son (25) randomized 214 patients to one of four treatment
groups (placebo, heparin, atenololor heparincombinedwith
atenolol). Patients treated with heparin had a reduced in-
cidence of myocardial infarction during their hospital stay
and during a follow-up of R weeks.
Wc recently performed a sequential study (26) in which
patients with successful coronary thrombolysis in the early
hours of myocardial infarction received either a continuous
heparin infusion or a 4 hour maintenance infusion of intra-
venous rt-rA and heparin. In the maintenance rt-PA group,
acute coronary reocclusion was efficiently prevented, whereas
in patients receiving heparin alone, acute reocclusion oc-
curred consistently in association with high grade residual
stenosis. This study indicated that a type II eccentric lesion
following successfu l reperfusion with rt-PA in patients with
acute myocardial infarction can be stabilized and retnrom-
basis prevented with the use of a maintenance rt-PA infu-
sion. This will also reduce the degree of residual stenosis
at 10 days. improve the morphologic appearance of the
lesion and eliminate residual intraluminal clot. These initial
results have been confirmed and extended in a randomized
study in 45 patients (23). These observations suggest that
a prolonged infusion of rt-PA can stabilize a highly throm-
bogenic. damaged endothelial surface in a coronary artery.
Thrombolytic Therapy With Recombinant
Tissue-Type Plasminogen Activator (rt-PA) in
Unstable Angina
Results of a randomized study (Table I). We have
extended the concept that a prolonged infusion of rt-PA can
stabilize a thrombogenic endothelial surface after reperfu-
sion of occlusive coronary thrombosis. and have performed
a randomized study (27) using a 12 hour infusion of rt-PA
and heparin compared with heparin alone in 24 patients with
unstable angina. One important characteristic of this study
was its strict entry criteria. Patients were eligible only if
they had chest pain at rest within 7 days, associated with
transient ST segment changes of at least 0.1 mY. Patients
withevidence of recent myocardial infarctionwere excluded
from the study.
All patients were treated with a standard drug regimen
consisting of nitrates, calcium channel antagonists, beta-
receptor blockers and heparin for 12 to 24 hours. Patients
were then randomi zed to a 12 hour intravenous infusion of
either placebo or to 1.75 mg/kg body weight rt-PA. The rt-
Table 1. Correla tions Among Drug Regimen . Angiographie Demonstrati on of Residual
Thrombus and Persistent Ischemic Even ts"
rt-PA
Placebo
Recurrent anginn
No angina
r < 0.001 P <: o.os
No Recurrent No
Thrombus Th rombus Angina Angina
0 I I I II
8 ., 6 5
p < 0.003
6 1
2 13
*Patients with unstable angina during heparin anticoagulation were treated with recombinant tissue-type
plasminogen activator (rl· PA) or placebo.
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Correlation among drug regimen. angiographic demonstration of reo
sidual thrombus. persistence of ischemic events and bleeding in patients
with unstable angina treated with recombinant tissue-type plasminogen
activator (n -PA). Ml = myocardial infarction; UA? z- unstable angina
pectoris.
PA was administered at a rate of 0.75 mglkg over the first
hour, followed by 0.5 mg/kg over the next 4 hours and 0.5
mg/kg over the last 7 hours. No differences between the
placebo and rt-PA groups with respect to any demographic
or clinical characteristics were observed. In particular, the
duration of unstable angina, the time from the qualifying
episodeof chest pain to entry in the study and the preinfusion
observation period were comparable in the two groups.
Coronary and left ventricular angiography was performed
1 to 3 days after completion of the infusion. All patients
were followed up in the hospital for a minimum of 4 days
during which time the frequency of ischemic events, need
for increasedanti-ischemic therapy, incidence of myocardial
infarction and sudden death were recorded.
Coronary angiograph y was performed in 22 of the 24
randomized patients . The time from the end of infusion to
coronary angiography was 35 hours in the placebo group
and 43 hours in the rt-Pa group (difference not signifi cant).
Placebo- and rt-Px-treated patients were similar with re-
spect to the severity of coronary artery disease, quantitative
stenosis and lesion morphology . Eightof II placebo-treated
patients had intracoronary thrombus. whereas none of II
rt-PA-treated patients had detectable thrombus (p < 0.002)
(Table I). Of the four patients in the placebo group with a
type II lesion, all had angiographic evidence of intracoro-
nary thrombus. In the rt-PA group, four patients had a type
II lesion but no evidence of thrombus and this difference in
the incidence of thrombus was significant. Ischemic symp-
toms persisted in 6 of 11 placebo-treated patients and in I
of 12 rt-PA-treated patients and this difference was also
significant. A highly significant correlation was observed
between thepresenceof thrombusand recurrentangina, with
six of the seven patients with recurrent angina having an
intracoronary thrombus.
Side effects of prolonged rt-PA infusion and heparin
anticoagulation in unstable angina. During the 12 hour
rt·PA infusion in the randomized study (27), fibrinogen
levels decreased to 66% of baseline after I hour and to 64%
of baselineafter 12 hours. Most of the fibrinogen breakdown
therefore occurred within the first hour, with very little
additional decrease thereafter. Plasma t-PA antigen levels
were5.6 j.Lg/ml after I hour, which is a highly thrombolytic
Table 2. Intravenous rt-PA withou: Heparin in
Unstable Angina
Placebo (n = 5)
rt-PA (n = 4)
Thrombus
3
3
UAP/MJ
2
2
Bleeding
o
3
level (28). Beyond 5 hours, the t-PA levels had fallen to
approximately one third of those seen in patients with myo-
cardial infarction during maintenance rt-PA infusion.
Bleeding was not observed in the placebo group bra
occurred in 8 of the 12 rt-PA-treated patients. Bleeding
from puncture sites occurred in four patients and major
superficial bleeding in another one. This necessitated pre-
mature termination of the infusion in three patients and
transfusionof 2 units of blood inone of these three. Bleeding
consistently occurredduring the second half of the infusion,
when l-PA levels were relatively low and fibrinogen levels
remained stable. The mechanism of this bleeding is not
obvious and requires further investigation.
Inadequacy of rt-PA infusion without heparin anti-
coagulation for unstable angina. In an attempt to deter-
mine whether the bleeding seen in the previous study (27)
was related to the combination of rt-PA and heparin. or
could be due to either agent alone, we have performed a
randomized study comparing therapy with rt-PA without
heparin with placebo. Interim analysis after treatment of
nine patients (fi ve with placebo, four with rt-PA) revealed
that rt-PA alone did not lyse intracoronary thrombus effi-
ciently, that patients failed to stabilize and that the bleeding
tendency was not eliminated (Table 2). Therefore the study
was prematurely terminated.
Conclusions
The characteristic coronary lesion in unstable angina is
a disrupted atherosclerotic plaque associated with intramural
and intraluminal thrombus. It is very similar if not identical
10 the lesion typically seen in acute myocardial infarction,
except for the less pronounced degree of thrombus forma-
tion. In patients withunstable angina, intraluminal thrombus
frequently persists, despite heparin anticoagulation. A pro-
longed (12 hours) infusion of rt-PA with heparin effectively
lyses thrombus and leads to stabilization of the clinical syn-
drome, but is associated with an unacceptably high inci-
dence of bleeding. Our future studies will be directed toward
defining subgroups of patients with unstable angina who
will most likely benefit from thrombolytic therapy and towards
the design of therapeutic schemes associated with a reduced
bleeding frequency.
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